Clinical Trials on Neuroectodermal Tumors, Primitive in Austria

Total 1204 results

Institut Curie

Active, not recruiting

Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)Opsoclonus Myoclonus Syndrome/Dancing Eye Syndrome (OMS/DES) in Children With and Without Neuroblastoma (NBpos and NBneg)

Neuroblastoma | Opsoclonus Myoclonus Syndrome

France, Austria, Italy, Spain, Sweden, Switzerland, United Kingdom
Medical University of Vienna

Completed

Non-invasive Evaluation of Fluid Status and Cardiac Output During Operative Treatment of Pheochromcytoma

Pheochromocytoma

Austria
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial

Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Lymphoma | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant... and other conditions

United States, Puerto Rico, Australia
Ipsen

Terminated

A Retrospective Data Analysis of Therapy With PRRT Combined With Lanreotide Autogel® for Neuroendocrine Tumours (PRELUDE)

Neuroendocrine Tumours

United Kingdom, France, Germany, Australia, Italy
The Netherlands Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Optimal Neo-adjuvant Combination Scheme of Ipilimumab and Nivolumab (OpACIN-neo)

Malignant Melanoma Stage III

Austria, Netherlands, Australia, Sweden
DNAtrix, Inc.
Merck Sharp & Dohme LLC

Completed

Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE)

Nervous System Diseases | Glioma | Glioblastoma | Neuroectodermal Tumors | Brain Cancer | Gliosarcoma | Brain Neoplasm | Malignant Brain Tumor | Neoplasm, Neuroepithelial | Neoplasm by Histologic Type | Neoplasm, Nerve Tissue

United States, Canada
Medical University of Vienna

Unknown

Genetic Risk Factors and Acquired Oncogenic Mutations of Melanoma (M3)

Melanoma

Austria
Pfizer
Children's Oncology Group (COG)

Active, not recruiting

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Ewing Sarcoma | Medulloblastoma | Rhabdoid Tumor | Neuroblastoma | Solid Tumors | Rhabdomyosarcoma | Diffuse Intrinsic Pontine Glioma

United States, Canada, India, Spain, United Kingdom, Belgium, Hungary, Brazil, Slovakia, Poland, Argentina, Bulgaria, Korea, Republic of, Czechia, Germany, Israel, Netherlands, France, Italy, Sweden, Turkey
National Cancer Institute (NCI)

Active, not recruiting

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Histiocytic and Dendritic Cell Neoplasm | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)

Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Glioma | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Puerto Rico
Medical University of Vienna

Terminated

Rituximab in Metastatic Melanoma

Metastatic Melanoma

Austria
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

Australia, United States
National Cancer Institute (NCI)
Children's Oncology Group

Active, not recruiting

Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent... and other conditions

United States, Puerto Rico
Ipsen

Terminated

Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs

Neuroendocrine Tumors

United States, Australia, Austria, Canada, Denmark, France, Switzerland, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Recurrent Childhood Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Solid Neoplasm | Recurrent Medulloblastoma | Recurrent Neuroblastoma | Recurrent... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

Sarcoma | Lymphoma | Kidney Cancer | Leukemia | Neuroblastoma | Oral Complications

United States, Israel, Australia, Canada
Medical University of Vienna

Recruiting

Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma

Uveal Melanoma

Austria
National Cancer Institute (NCI)

Active, not recruiting

Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)

Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Malignant Glioma | Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Completed

Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors

Recurrent Neuroblastoma | Recurrent Osteosarcoma | Recurrent Childhood Rhabdomyosarcoma | Recurrent Adult Soft Tissue Sarcoma | Recurrent Wilms Tumor and Other Childhood Kidney Tumors | Previously Treated Childhood Rhabdomyosarcoma | Recurrent Childhood Soft Tissue Sarcoma | Adult Rhabdomyosarcoma | Neuroectodermal Tumor and other conditions

United States, Canada, Australia
Medical University of Vienna

Unknown

Disease Progression and Treatment-induced Alterations in Glioblastoma

Brain Tumor

Austria
Medical University of Graz

Completed

Suction Drain in Axillary Lymph Node Dissection for Malignant Melanoma

Malignant Melanoma

Austria
Jagiellonian University
Medical University Innsbruck; University Medical Centre Ljubljana; University... and other collaborators

Completed

Novel 99mTc-labeled Somatostatin Antaginosts in the Diagnostic Algotithm of Neuroendocrine Neoplasms (TECANT)

Neuroendocrine Tumors

Austria, Poland, Slovenia
Provectus Biopharmaceuticals, Inc.

Active, not recruiting

A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver

Neuroendocrine Tumors Metastatic to the Liver

Australia
Medical University of Vienna

Completed

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

Stage IV Melanoma | Stage III Melanoma

Austria
Ipsen

Completed

Somatuline Predictive Factors in Acromegaly and NET (SOPRANo)

Acromegaly | Neuroendocrine Tumours

Switzerland, Austria, Germany
Kepler University Hospital

Recruiting

Immuno-Positron Emission Tomography (PET)-Glioma Study, a Proof-of-principle Imaging Study

Glioblastoma

Austria
Ipsen

Terminated

A Study to Collect the Somatuline® Injector Device Preferences of Patients Living With Neuroendocrine Tumor (NET) and Nurses Involved in the Care of Patients With NET

Neuroendocrine Tumors

Australia
Lipotek Pty Ltd
Royal Adelaide Hospital; Trident Clinical Research Pty Ltd

Completed

Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma

Melanoma

Australia
Telix International Pty Ltd

Recruiting

131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2) (IPAX-2)

Glioblastoma | Glioblastoma Multiforme | Neoplastic Disease

Australia, Austria, Netherlands, New Zealand
BioNTech RNA Pharmaceuticals GmbH

Completed

RBL001/RBL002 Phase I Clinical Trial (MERIT)

Melanoma

Austria, Germany
Ipsen

Completed

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET (SONNET)

Gastroenteropancreatic Neuroendocrine Tumors

Germany, Austria
BioNTech RNA Pharmaceuticals GmbH

Completed

IVAC MUTANOME Phase I Clinical Trial

Melanoma

Austria, Germany
Medical University of Graz
Bristol-Myers Squibb

Terminated

The IRMI-FMT Trial

Malignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota Transplantation

Austria
Telix International Pty Ltd

Completed

131I-IPA and Concurrent XRT in Recurrent GBM (IPAX-1)

Glioblastoma Multiforme

Austria, Australia, Netherlands
Clarity Pharmaceuticals Ltd

Active, not recruiting

A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)

Neuroendocrine Tumors

Australia
Camurus AB

Active, not recruiting

A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET (SORENTO)

Gastro-enteropancreatic Neuroendocrine Tumor

United States, Belgium, Spain, Netherlands, France, Germany, Israel, Italy, Canada, Australia, Romania, Hungary
Philogen S.p.A.

Completed

Intratumoral Application of L19IL2 in Patients With Malignant Melanoma

Malignant Melanoma

Austria, Germany
Peter MacCallum Cancer Centre, Australia

Recruiting

PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours (PARLuNET)

Neuroendocrine Tumors

Australia
Medical University of Vienna

Recruiting

Uveal Melanoma - Comparative Study

Uveal Melanoma

Austria
National Cancer Institute (NCI)

Active, not recruiting

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico
Medical University of Vienna

Recruiting

Retrospective Register for Uveal Melanoma

Uveal Melanoma

Austria
University Hospital Heidelberg
German Cancer Research Center

Recruiting

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies (INFORM2 NivEnt)

Solid Tumor | CNS Tumor

France, Germany, Australia, Austria, Sweden, Netherlands, Switzerland
Onxeo

Completed

A Study to Assess APO866 for the Treatment of Advanced Melanoma

Melanoma

Austria, France, Germany, Switzerland
Peter MacCallum Cancer Centre, Australia

Recruiting

Metabolic Phenotypes in Melanoma (MetaMel)

Melanoma

Australia
Bristol-Myers Squibb

Completed

A Study of Adjuvant Melanoma Stakeholder Treatment Preferences

Melanoma

Australia
Medical University of Graz

Completed

The Impact of Total Body Skin Examination on Skin Cancer Detection (TBSE)

Melanoma | Skin Cancer | Merkel Cell Carcinoma | Basal Cell Carcinoma | Squamous Cell Carcinoma

Austria
Medical University of Vienna

Recruiting

Longitudinal Follow-Up of Patients Treated With Hypofractionated Stereotactic Photon Radiotherapy Due to Uveal Melanoma

Uveal Melanoma

Austria

Clinical Trials on Neuroectodermal Tumors, Primitive in Austria

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations